BACKGROUND: Seve ral microtubule targ eting ag enls are capab le of inducing CYP3A4 via activation of the pregnane X receptor (PXR; NR 112).
regulating the transcription of genes involved in xenobiotic metabolism andtransport.I! Theobjective of thisstudy wasto evaluate whether vinblastine also acts as an inducer of CYP3A4,both in vivo and in vitro, and, if so, to determine theroleofNRII2 in thisprocess.
Methods

PATIENTS
A total of 6 patients (Table I) , who were enrolled in a Phase 1/2 study of infusional vinblastine given in combination with the ABCB 1 (P-glycoprotein) antagonist valspodar (PSC 833) 16 and received the CYP3A4 phenotyping probe midazolamon more than I occasion,were included in this study.All patients were white and had a diagnosisof renal cellcarcinoma. Inclusion andexclusion criteria havebeendescribed previously andall patients hadadequate hepatic function(aspartate aminotransferase <25 times the upperlimitof normal; total bilirubin <15 times theupper limit of normal)," Based on the knowledge that valspodar is metabolized by CYP3A4,1' the sameenzymethat is involved in cyclosporine metabolism, the use of strong inducers of cyclosporine metabolism or CYP3A4 (including nafcillin, rifampin,carbamazepine,phenobarbital,and phenytoin) or the use of inhibitors (including diltiazem, nicardipine, verapamil, fluconazole, clarithromycin, erythromycin, bromocriptine, and danazol) was avoided. The studywas approved by the institutional review boardandallpatients gaveinformed consent.
DRUG ADMINISTRATION
Valspodar, vinblastine, and midazolam were obtained from commercial sources by the National Institutes of Health Clinical Center Pharmacy Department, Bethesda, MD. Briefly, valspodar was prepared for a 24-hour infusion (50 mg/mL in polyoxyethylated castor oil [Cremophor EL] diluted in 250 mL or 500 mL of 5% dextrose or 0.9% sodiumchloride) and was administered on the first 2 days of therapy in cycle 1 followed 4 days later by a 6day infusion of valspodar. Vials containing 10 mg of lyophilized vinblastine were reconstituted and the drug was then furtherdiluted in 250 mL of sterile0.9% sodium chloride injection. Vinblastine was given as a 3-day continuous intravenous infusion, which began 24 hours after the initiation of valspodar (1-2.6 mg/mvday) every 28 days (days 9-11 of cycle I and days 2-4 during subsequentcycles). Midazolam was administered as an intravenousbolus injection at a dose of 0.0145 mglkg on day 1 of cycles 1 and 4 to assess phenotypic CYP3A4activity.
MIDAZOLAM PHARMACOKINETICS
Blood samples were drawn into heparinized tubes at 0.083,0.25,0.5, 1,2,3,4, and 5 hours following midazolam administration. Samples werecentrifuged immediately to obtain plasma, which was stored at -80°C until analysis. Plasmaconcentrations of midazolam were determined by high-performance liquid chromatography with mass spectrometric detection, as described previously." The lower limit of quantitation of this assay is 1 ng/mL, with values for precision and accuracy of s15% and <12% relative error, respectively. Pharmacokinetic parameterswere determined by noncompartmental analysis using WinNonlin version 4.0 (Pharsight Corporation, Mountain View, CA). The area under the plasma concentration versus time curve (AUq was calculated using the linear trapezoidal method from time zero to the time of the final quantifiable concentration. The AUC was then extrapolatedto infinity by dividing the last measured concentration by the rate "constant of the terminal phase (k), which was determined by linear-regression analysis of the final 3 time points of the log-linear concentration-time plot. All reported AUC values were dose normalized. The systemic clearance of midazolam was calculated by dividing the administered dose in milligrams by the observed AUe.
STATISTICAL ANALYSIS
Basedon the standard deviation of the changesexpected in phenotypic CYP3A4 activity (Sd) , a power (l-~) of 0.8 DNA was isolated from plasma and individual CYP3A4*lB (-392A>G; 5'-regulatory region; dbSNP rs ID number,rs2740S74; see http://www.ncbLnlm.nih.govl), CYP3A4*17 (lS6IST>C; F189S; rs4987161), CYP3A4*18A (20070T>C; L293P; no rs ID number), CYP3A5*3C (6986A>G; splicing defect; rs776746), CYP3A5*6 (14690G>A; splicing defect; rsI0264272), and ABCBl (MDRl) (343SC>T; 111451; rsl04S6S2)genotypes were determined as described previously,"
WESTERN BLOTnNG
HepG2 cells, maintained in RPMI 1640 supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, were treated with vinblastine (150-4800 ng/mL) for 48 hours. CYP3A4 protein expression was determined by Westernblot analysis as described previously," For microsome preparation,cells were centrifuged at 750 x g for 5 minutes and washed immediately in a storage buffer composed of 50 mM potassium phosphate, 1 mM EDTA, and 20% glycerol(pH 7.4). This was followedby homogenization using a glass-Teflon homogenizer and a buffer containing 1.15M potassiumchloride, 10 mM EDTA, 100 mM potassium phosphate, and 0.2 mM phenylmethylsulfonyl fluoride (pH 7.5). Following differential centrifugation (l2,OOO x g for 12 minutes; 100,000 x g for 90 minutes), the pellet was resuspended in storage buffer to a concentration of 4 mg/mL. Fifty micrograms of microsomal protein were loadedper lane and transferred to a nitrocellulose membrane following separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Human CYP3A4 + reductase BD Supersomes (BD Biosciences, Bedford, MS) were used as a positive control. The WB-MAB-3A mouse monoclonal antibody and an HRP-conjugated rabbit anti-mouse IgO were purchased from BD Biosciencesand diluted as per manufacturer's instructions. Bands on film were optically scanned (Epson Expression 1600,San Diego, CA).
Induction o/CYP3A4 by Yinblastine:Role ofthe Nuclear ReceptorNR1l2
TRANSIENT TRANSFECnON EXPERIMENTS The reporterplasmids pSGS-hPXR (human NR1I2) and pSGS-rnPXR (mouse NR1I2) were providedby Dr.Steven Kliewer (University of Texas Southwestern Medical Center, Dallas, TX). 20 The reporter plasmids pDR-hCAR (human NR1I3) and pcDNA3-mCAR (mouse NRII3) were provided by Drs. David Moore (Baylor College of Medicine, Houston, TX) and Masahiko Negishi (National Institute of Environmental Health Sciences, Research Triangle Park, NC), respectively. The CYP3A4-PXRE-LUC reporter plasmid containing the proximal promoter (-362/+53) and distal XREM (-7836/-7208) was prepared as previously described." Vinblastine (Sigma-Aldrich,St. Louis, MO) and valspodar(Novartis Pharmaceutical Corp., East Hanover, NJ; distributed by the Cancer Therapy Evaluation Program, National Cancer Institute,Bethesda,MD) were dissolvedin dimethyl sulfoxide (DMSO) and storedat -20°C. HepG2 and NIH3T3 cells were maintained in minimum Eagle's medium supplemented with 10% fetal bovine serum, I % penicillin-streptomycin, and 1% t-glutamine. Experiments were performed as described previously." Briefly, approximately 3 x lOS cells were seeded into 24well plates, 24 hours before co-transfection by calcium phosphateprecipitation with 0.5 ug of the reporterplasmid and 0.1 }tg of the expression plasmidor empty vector plasmid. The SV40-f3-galactosidase controlvector (0.1 }tg) was used as an internal control for transfection efficiency. Twelve hours later, cells were washed and then incubated with drug prepared in medium containing 10% charcoal dextran-treatedfetal bovine serum (Hyclone Laboratories, Logan, UT) for 24 hours. Cells were harvested, lysed, and centrifuged at 1500 xg for 4 min, and an aliquot of supernatant was used to determine luciferase (Luciferase Assay System, Promega, Madison, WI) and f3-galactosidase (13-Galactosidase Enzyme Assay System, Promega, Madison, WI) activities according to the manufacturers' instructions. Luciferase activity was normalized to I3-galaetosidase activity. All experiments were performed twice in triplicate.As positivecontrols,rifampin and pregnenolone-I6a-carbonitrile (PCN) were used for human and mouse NRII2, and CITCO (6-(4-chlorophenyl)imidazo [ 
Results
IN VIVO STUDY
The CYP3A4 phenotyping probe midazolam (0.0145 mg/kg) was administered by intravenous bolus to 6 patients with renal cell carcinoma undergoingtreatment with vinblastine (72-hour intravenous infusion given every 28
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The Annals ofPharmacotherapy • 2010November, Volwne 44 • 1711 days). None of the patients received any prescription drug other than vinblastine that is known or suspected to alter CYP3A4 activity that could have confounded the results, albeit that valspodar is a very weak CYP3A4 inhibitor." Midazolam clearance and AVC were determined on day 1 and during cycle 4 (days 92-119; Figure 1 ). On day 1 of cycle 1, the clearance of midazolam ranged from 16.2 to 28.1 Llh (median 21.7; 95% CI 12.6 to 28.1). All 6 patients exhibited increased midazolam clearance between cycle 1 and cycle 4, indicative of increased CYP3A4 activity following repeat administration of vinblastine (Figure 1 
IN VITROCYP3A4PROTEIN EXPRESSION
Expression of CYP3A4 protein was determined following exposure of HepG2 cells to vinblastine for 48 hours at concentrations ranging between 150 and 4800 ng/mL. Vinblastine, at concentrations of 300 ng/mL and above, substantially increased CYP3A4 protein expression compared to that seen in DMSO -treated control cells ( Figure   2 ).
REPORTER GENE ASSAYS
Cell-based luciferase reporter gene assays for the determination of NR1I2 transcriptional activity were performed to establish whether vinblastine is an activating ligand of NR1I2. HepG2 cells were transiently transfected with the expression plasmid for full-length human NR1I2 (pSG5-hPXR) or mouse NR1I2 (pSG5-rnPXR) and the respective luciferase reporter plasmids. Treatment with vinblastine resulted in a concentration-dependent increase in transcriptional activity of both human and mouse NR1I2 (Figure 3 ). The extent of activation by vinblastine (2-fold to 3-fold), however, was relatively weak compared to that of the positive controls rifampin and PCN, respectively, which resulted in a 5-fold to 8-fold increase in reporter activity. Vinblastine had no effect on the transcriptional activity of human and mouse full-length NRII3 in transiently transfected NIH3T3 cells (Figure 4 ). Increased activity of the reporter was not observed after treatment with valspo- Discussion dar, suggesting that this compound is not an activating ligand of NR1I2 or NR 113 ( Figure 3 and Figure 4 ). tion of CYP3A4. Midazolam does not interact with ABCB 1. 24 In addition to vinblastine, patients received the ABCBl inhibitor valspodar," which might be considered a drawback of this study. However, since valspodar is reported to be a potential competitive inhibitor of CYP3A4,1' it is unlikely that this agent contributed to the observed induction of this drug-metabolizing enzyme; rather, valspodar would be expected to mask the effect of vinblastine on the clearance of midazolam. Moreover, valspodar is only a very weak inhibitor of midazolam metabolism through CYP3A4/5 in human liver microsomes, and selective ABCB 1 inhibitors do not affect midazolam clearance mechanisms in humans.P" To provide mechanistic evidence that induction of CYP3A4 expression by vinblastine is responsible for the increase in midazolam clearance observed clinically, HepG2 cells were exposed to increasing concentrations of vinblastine for 48 hours. Consistent with the clinical observation, vinblastine substantially induced CYP3A4 protein expression in vitro, even at low concentrations. The majority of compounds that induce CYP3A4 do so via activation of the nuclear receptor NR 112. Furthermore, this has recently been shown to be the mechanism of CYP3A4 induction by other microtubule-targeting agents, including 
Midazolam AUC
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The Annals ofPharmacotherapy • 2010 November, Volume 44 • 1713 paclitaxel and epothilones.t-" and the mechanism ABCB 1 induction through vinblastine itself at a higher concentration (10 ]lM. or 8110 ng/ml.)." Therefore, cell-based luciferase reporter gene assays were performed to determine whether vinblastine is an activating ligand of NR 112 between 150 ng/mL and 4800 ng/mL. The results from these experiments suggest that vinblastine is a weak activator of both human and mouse NRII2 and that the observed induction of CYP3A4 expression is likely to occur, at least in part. via an NRII2-dependent mechanism. Of note, activation of another closely related nuclear receptor that can regulate CYP3A4. namely NRII3,27by vinblastine was not observed, even at high concentrations. However, activation of another nuclear receptor that can regulate CYP3A4. such as the vitamin D receptor (NRIIl),28.31 or the glucocorticoid receptor (NR3CI).32 cannot be excluded. Additionally. CYP3A4 induction may occur as a post-translational event as a result of stabilization of mRNA or decreased protein turnover. The observed induction of CYP3A4 by vinblastine has considerable clinical implications. First. since vinblastine itself is a substrate of this enzyme," autoinduction leading to accelerated metabolism may occur in patients receiving vinblastine over prolonged periods. Second. there is the possibility for a previously unrecognized type of pharmacokinetic interaction between vinblastine and concomitantly administered drugs that are CYP3A4 substrates. Both of these events could result in altered efficacy or toxicity of the drugs involved. Indeed. CYP3A4 induction by vinblastine may provide a plausible explanation for the outcomes of 2 earlier clinical studies involving this drug. 33 ,34 For example, it was reported that treatment of patients with testicular cancer using a combination regimen of cisplatin, vinblastine, and bleomycin resulted in a 30% increase in the clearance of antipyrine, which lasted for 6 weeks." Although antipyrine is metabolized by several CYP isoenzymes, CYP3A4 is responsible for the formation of a major metabolite. 4-hydroxyantipyrine. 35 Additionally. the combination of paclitaxel, vinblastine, and cisplatin was found to be less effective and less toxic than expected in the treatment of advanced transitional cell carcinoma of the urothelium." In this combination, vinblastine was adminis- tered as a boluspriorto paclitaxel, whichis veryextensively metabolized by CYP2C8 and CYP3A4. 36 ,37 Thus, induction of the CYP3A4-mediated metabolism of paclitaxel by vinblastine could contribute to the low response rate and the low incidence of peripheral neuropathy reported. However, vinblastine was administeredas a bolus injection in the above study, while our data were obtained in patients receiving a continuous infusion, and it remains unclear whether or not the inductive effect on CYP3A4 through vinblastine treatment is schedule dependent in vivo. Finally, there is substantial evidence for the involvement of CYP3A4 in the metabolism of other vinca alkaloids in addition to vinblastine. Studies with human liver microsomesrevealed that CYP3A4 is responsible for the metabolism of vindesine." Vincristine and vinorelbine were shown to inhibit vinblastine metabolism," and vincristine also inhibited the metabolism of dihydropyridine denitronifedipine,' The CYP3A4-inducing antiepileptic agents carbamazepine and phenytoin increased the clearanceof vincristinein patients withbraintumors.' Furthermore, nifedipine and itraconazole,which are inhibitors of CYP3A4, decreased the clearance" and increased the neurotoxicity! of vincristine, respectively. Sincevinblastine acts as an inducer of CYP3A4, in addition to being a substrate and inhibitor of thisenzyme, it is possible that similar induction phenotypes are associated withothervincaalkaloids.
In conclusion, this study indicates that vinblastine acts as an inducer of CYP3A4 bothclinically and in vitro.Similar to other microtubule-targeted agentsknown to induce CYP3A4, induction of CYP3A4 by vinblastine appears to occur, at least in part, via an NR1I2-dependent mechanism. This observation has clinical ramifications not only for vinblastine, but also for other vincaalkaloids in clinical use or development. RFsULTATS: Chez6 patients cancereux.Iavinblastine a accrulaclairance rnediane (IC 95%)de 1a sondemidazolam de phenotypage CYP3A4 de 21.7(12.6-28.1) Uh a 323 (173-53.9) Uh (p =0.0156,testdes rangs signes[Wilcoxon]). Aucun effetde polyrnorphisrne evident dans CYPJA4,CYP3A5,et ABCBI sur la c1airance du midazolam ne fut observe. In vitro.Ia vinblastine induitla proteine CYP3A4. En outre,les reporter gene assaysutilisantlescellules transfectees transitoires HepG2 et NIH3T3 ont indique que la vinblastine (150-480 mglmL) a active faiblernent louiela longueur du gene NR112 chez les sujetshumains et les souris,maiscependant n'a eu aucune influence sur NRI13.
InductionofCYP3A4 by Vinblastine: Role ofthe NuclearReceptorNR1l2
CONCLUSIONS: De maniere collective. ces resultats suggerent que la vinblastine est capabled'induireCYP3A4, ou toutau moins en partie, via un mecanisme NRI12dependant. Ainsi, il possede un potentiel pour faciliter sa propreelimination et causedes interactions avecd'autres substrats CYP3A4. The 14th edition includes a "do not use" list of dangerous abbreviations in addition to the 30,000 meanings for the abbreviations, acronyms,and symbols.The book also contains a cross-referenced list of 3,400 generic and trade drug names. Each copy includes a single-useraccess license for the web version of the book which is updated withover 80 newentries per month. This license is valid for 12 months from the date of initial log-in.
Essential to medical professionals for order interpretation, data entry,unit dose cart filling, and prescription interpretation. A mustto ensurepatientsafety and reduce medication errors.
